Apr 25, 2025Abstract Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known about nutrientintakewhile using aGLP-1RA. The purpose of this study was to compare nutrientintakewhile using aGLP-1RA to the Dietary ReferenceIntakes(DRI). Methods:
Methods This narrative literature review summarizesclinicalstudies quantifying and characterizing dietaryintakein people with obesityand/or T2DM usingGLP-1or GIP/GLP-1 RAs. Results Though data from these studies reveal that total caloricintakewas reduced by 16-39 %, few studies evaluated the actual composition of the diet. Conclusions
Middle-aged women with (overweight/)obesity who will begin or have begunGLP-1medication use will be recruited to complete a 12-week diet intervention study. For 12-weeks, participants will continue to take theirGLP-1medication and may be provided withprotein-rich foods to consume every day. Body composition, eating behavior, health, and well-being will be measured before and after the study.
This narrative review provides an overview of the latest research onprotein-andcalcium-mediatedGLP-1release with an emphasis on human data, and a perspective on potential mechanisms that link potentGLP-1release to the co-ingestion ofproteinandcalcium.
Mar 20, 2025Interventional Model Description: This will be a 6-month 4 arm (control, resistance exercise,proteinintakeandresistance exercise +proteinintake) randomised controlledtrialin people with obesity upon initiation of semaglutide/tirzepatide therapy.
May 30, 2025Emerging areas for more study include dietary modulation of endogenousGLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria forclinicalobesity.
Jun 16, 2025WhileGLP-1shave been an effective weight loss tool, the firstclinicalGLP-1nutrition study shows they can lead to lowproteinandessential nutrientintakePittsburgh, PA, June 17, 2025 — GNC, the leading global health and wellness retailer, continues its dedication to support individuals usingGLP-1agonists in new groundbreaking scientific research revealing the first-ever real-world ...
Nov 23, 2025Eligible studies includedclinicaltrials, observational cohorts, and reviews reporting nutritional outcomes inGLP-1RA users or describing MBS monitoring guidelines. Results:GLP-1RA therapy consistently reduced caloricintake, with frequent inadequacy ofproteinintakeandoccasional sarcopenia.
Glucagon-like peptide-1 (GLP-1) is an enterohormone with a key role in several processes controlling body homeostasis, including glucose homeostasis and foodintakeregulation. It is secreted by the intestinal cells in response to nutrients, such as glucose, fat and amino acids. In the present review, we analyse the effect ofproteinonGLP-1secretion and clearance. We review the literature ...
Distributeproteinintakeevenly throughout the day to maximizeproteinsynthesis. Focus on high-quality sources (animal, dairy and soy) rich in essential amino acids)
Mar 14, 2026Middle-aged women with (overweight/)obesity who will begin or have begunGLP-1medication use will be recruited to complete a 12-week diet intervention study. For 12-weeks, participants will continue to take theirGLP-1medication and may be provided withprotein-rich foods to consume every day. Body composition, eating behavior, health, and well-being will be measured before and after the study.
TodayWorking with a provider, eating well, staying hydrated, and maintainingproteinintakeandexercise can reduce side effects and help preserve muscle during weight loss. OrderlyMeds provides medically supervisedGLP-1andGLP-1/GIP treatment with ongoing provider access, personalized dosing, and nutrition support.
Ever notice howGLP-1results in studies look amazing… but real-life experiences can feel very different? Here's the part most people don't realize 👇 Inclinicaltrials, participants aren't just given medication. They're given structure: • regular check-ins with a registered dietitian • guidance on balanced meals andproteinintake• support for side effects, energy, and ...
1 day agoA living library of peer-reviewed research onGLP-1medications combined with lifestyle interventions — nutrition, exercise, coaching, muscle preservation, and weight regain prevention. Updated regularly.
5 days agoMiddle-aged women with (overweight/)obesity who will begin or have begunGLP-1medication use will be recruited to complete a 12-week diet intervention study. For 12-weeks, participants will continue to take theirGLP-1medication and may be provided withprotein-rich foods to consume every day. Body composition, eating behavior, health, and well-being will be measured before and after the study.
5 days agoShould I Increase Dose? Increasing the dose of aGLP-1medication can improve weight loss in some cases.Clinicaltrialsshow a clear dose response effect. Dose changes should only be made under clinician guidance. A provider will assess safety, tolerance, and overall progress before adjusting treatment.
See exactly how much weight people lose per month onGLP-1medications like semaglutide and tirzepatide, withclinicaltrialdata and real world results.
Learn exactly how muchproteinto eat on semaglutide. Research-backed daily targets, meal plans, and strategies to preserve lean muscle duringGLP-1weight loss.
5 days agoIn addition, the team will examine other health and behavior measures, includingintakeofprotein, fruits, and vegetables; participation in muscle-strengthening activities; confidence in maintaining healthy habits; muscle mass; body weight; waist circumference; and blood pressure.
Feb 25, 2026Caloric restriction is a cornerstone of weight loss and metabolic health interventions; however, it is consistently associated with unintended reductions in lean body mass.Clinicalevidence indicates that pharmacologic-induced caloric restriction involvingGLP-1receptor agonists (GLP-1RAs) consistently produces substantial weight loss (~10-15% of baseline body weight). This is consistently ...
TodayClinicaltrialshave documented that patients who lose more than 20% of their body weight are at higher risk for hair shedding. Several factors can increase the likelihood of experiencingGLP-1hair loss:
Sep 18, 2024The glucagon-like peptide-1 (GLP-1) receptor, known asGLP-1R, is a vital component of the Gprotein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types ...
5 days agoA phase 2clinicaltrialfound that combining semaglutide with the antibody bimagrumab led to greater weight loss and better preservation of lean muscle than semaglutide alone. Bimagrumab appears to promote muscle growth and reduce body fat. The combination treatment is not yet FDA-approved, and experts say resistance training and adequateproteinintakeremain key for preserving muscle during ...
4 days agoBackground andClinicalContext Muscle loss in patients onGLP-1receptor agonists (GLP-1RAs) was initially underplayed. However, responsible clinicians have consistently and strongly encouraged ...
2 days agoAndhonestly? The results people are seeing withGLP-1medications like Ozempic, Wegovy, and Mounjaro are real.Clinicaltrialsshow that semaglutide alone can help people lose around 12% of their body weight, and tirzepatide pushes that to roughly 18%.
5 days agoThe consequences are lowerproteinintake, micronutrient deficiencies and reduced dietary diversity. The shift is cumulative and rarely immediate and that is why people do not notice it happening. One of the most under-discussed outcomes ofGLP-1therapy is lean mass loss. Patients lose muscle, which introduces a cascade.
TodayThe good news is that nutritional deficiencies onGLP-1medications are preventable. Here are some practical steps that come directly from the research andclinicalrecommendations.1. Eat the important stuff first When your appetite is small, the order matters. Prioritizeprotein, fruits, and vegetables before filling up on toast or crackers.
3 days agoReduced foodintakeonGLP-1medications makes supplementation worth considering if dietary sources aren't consistently meeting these targets. Our article on vitamin D and semaglutide covers the vitamin D question in more depth, including what levels to aim for and how to monitor status during treatment.
The Lean Mass Question DuringGLP-1Weight LossGLP-1medications are among the most effective pharmacologic tools currently available for obesity and metabolic disease management.Clinicaltrialshave demonstrated significant improvements in weight, glycemic control, and cardiometabolic risk factors.
Muscle loss:GLP-1drugs reduce overall caloricintake,andproteinintakeoften falls short. Research published in Frontiers in Nutrition (2025) found that the balance of nutrients consumed shifts significantly, withproteinintakesometimes falling below maintenance levels.